抗表皮生长因子受体单抗治疗晚期结直肠癌疗效预测因子的研究

 研究证实抗表皮生长因子受体（EGFR）单克隆抗体西妥昔单抗和帕尼单抗是晚期结直肠癌的有效治疗药物，采用免疫组织化学测定的EGFR表达强弱与临床疗效无关。介绍了目前有可能预测从西妥昔单抗或帕尼单抗治疗中受益的标志物，包括KRAS突变、EGFR拷贝数、EGFR配体（EGF、表皮调节素和双调蛋白）、细胞周期蛋白D1、IgG FcγR（FCGR2A-H131R和FCGR3A-V158F）和核因子κB。这些标志物将在避免抗EGFR治疗毒性、减少治疗费用方面起到重要作用。

Identifying predictive markers of efficacy in antiepidermal growth factor receptor therapies in metastatic colorectal cancer

The antiEGFR monoclonal antibodies cetuximab and panitumumab have been proven to be efficient in MCRC. The degree of EGFR expression (as confirmed by immunohistochemical analysis) did not correhte with the clinical response. In this review, we describe the current status of markers that might identify patients who are likely to benefit from treatment with cetuximab or panitumumab. These molecular markers include KRAS mutations, EGFR copy number, EGFR ligands (EGF, epiregulin), cyclin DI, IgG FcγR (FCGR2A-HI31R and FCGR3A-V158F), and nuclear factor-κB, that are crucial to avoid anti-EGFR treatment toxicity and reduce treatment cost.